Literature DB >> 28868348

Targeting pseudokinase TRIB3 brings about a new therapeutic option for acute promyelocytic leukemia.

Ke Li1, Feng Wang2, Zhuo-Wei Hu2.   

Abstract

Pseudokinase tribbles (Trib) family, Trib1 and Trib2, but not Trib3, act as oncogene to drive acute leukemia by destabilizing the myeloid transcription factor CCAAT/enhancer-binding protein α (C/EBPα) and inhibiting myeloid differentiation. A recent study identifies pseudokinase TRIB3 as an important factor in acute promyelocytic leukemia (APL) progression and therapy resistance. Targeting TRIB3 may provide a novel therapeutic approach for APL.

Entities:  

Keywords:  AML; UPS; protein quality control; protein-protein interactions; sumoylation; tribbles; α-helical peptide

Year:  2017        PMID： 28868348      PMCID： PMC5540211          DOI： 10.1080/23723556.2017.1337547

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  A sumoylation site in PML/RARA is essential for leukemic transformation.

Authors:  Jun Zhu; Jun Zhou; Laurent Peres; Florence Riaucoux; Nicole Honoré; Scott Kogan; Hugues de Thé
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

Review 2.  Inhibition of α-helix-mediated protein-protein interactions using designed molecules.

Authors:  Valeria Azzarito; Kérya Long; Natasha S Murphy; Andrew J Wilson
Journal:  Nat Chem       Date:  2013-03       Impact factor: 24.427

3.  Resistance to therapy in acute promyelocytic leukemia.

Authors:  Jacqueline Lehmann-Che; Cecile Bally; Hugues de Thé
Journal:  N Engl J Med       Date:  2014-09-18       Impact factor: 91.245

4.  TRIB3 Promotes APL Progression through Stabilization of the Oncoprotein PML-RARα and Inhibition of p53-Mediated Senescence.

Authors:  Ke Li; Feng Wang; Wen-Bin Cao; Xiao-Xi Lv; Fang Hua; Bing Cui; Jiao-Jiao Yu; Xiao-Wei Zhang; Shuang Shang; Shan-Shan Liu; Jin-Mei Yu; Ming-Zhe Han; Bo Huang; Ting-Ting Zhang; Xia Li; Jian-Dong Jiang; Zhuo-Wei Hu
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

5.  Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.

Authors:  Pauline Isakson; Magnar Bjørås; Stig Ove Bøe; Anne Simonsen
Journal:  Blood       Date:  2010-06-23       Impact factor: 22.113

6.  TRB3 interacts with SMAD3 promoting tumor cell migration and invasion.

Authors:  Fang Hua; Rong Mu; Jinwen Liu; Jianfei Xue; Ziyan Wang; Heng Lin; Hongzhen Yang; Xiaoguang Chen; Zhuowei Hu
Journal:  J Cell Sci       Date:  2011-09-06       Impact factor: 5.285

7.  Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia.

Authors:  Letetia Jones; Guangwei Wei; Sabina Sevcikova; Vernon Phan; Sachi Jain; Angell Shieh; Jasmine C Y Wong; Min Li; Joshua Dubansky; Mei Lin Maunakea; Rachel Ochoa; George Zhu; Thelma R Tennant; Kevin M Shannon; Scott W Lowe; Michelle M Le Beau; Scott C Kogan
Journal:  J Exp Med       Date:  2010-11-08       Impact factor: 14.307

8.  A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657.

Authors:  Jastinder Sohal; Vernon T Phan; Philip V Chan; Elizabeth M Davis; Bhumi Patel; Louise M Kelly; Tinya J Abrams; Anne Marie O'Farrell; D Gary Gilliland; Michelle M Le Beau; Scott C Kogan
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

Review 9.  Tribbles in acute leukemia.

Authors:  Kai Ling Liang; Loveena Rishi; Karen Keeshan
Journal:  Blood       Date:  2013-04-02       Impact factor: 22.113

10.  TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations.

Authors:  Fang Hua; Ke Li; Jiao-Jiao Yu; Xiao-Xi Lv; Jun Yan; Xiao-Wei Zhang; Wei Sun; Heng Lin; Shuang Shang; Feng Wang; Bing Cui; Rong Mu; Bo Huang; Jian-Dong Jiang; Zhuo-Wei Hu
Journal:  Nat Commun       Date:  2015-08-13       Impact factor: 14.919
  10 in total
  1 in total

1.  PML-RARα interaction with TRIB3 impedes PPARγ/RXR function and triggers dyslipidemia in acute promyelocytic leukemia.

Authors:  Ke Li; Feng Wang; Zhao-Na Yang; Bing Cui; Ping-Ping Li; Zhen-Yu Li; Zhuo-Wei Hu; Hong-Hu Zhu
Journal:  Theranostics       Date:  2020-08-15       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.